Kidney Transplantation Clinical Trial
Official title:
The Effect of Remote Postconditioning on Graft Function in Patients Undergoing Living-related Kidney Transplantation
Verified date | December 2013 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to investigate whether upper limb ischemic postconditioning can improve renal function and decrease ischemic-reperfusion injury in patients undergoing living donor kidney transplantation.
Status | Completed |
Enrollment | 60 |
Est. completion date | May 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Subjects undergoing elective living donor kidney transplantation - subjects older than 20 yrs who can give written informed consent Exclusion Criteria: - re-transplant recipients - those with peripheral vascular disease affecting the upper limbs free of arteriovenous fistula |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Seoul Hospital, Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | 1 day before surgery | No |
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | at 2 h after declaming of renal artery | No |
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | at 6 h after declaming of renal artery | No |
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | at 12 h after declaming of renal artery | No |
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | at 24 h after declaming of renal artery | No |
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | at 48 h after declaming of renal artery | No |
Primary | renal function of recipient after living-related kidney transplantation | serum creatinine concentration and urine output | at 72 h after declaming of renal artery | No |
Secondary | Biomarkers of acute kidney injury | biomarkers of acute kidney injury: Plasma cystatin-C, Urine IL-18, Urine Neutrophil gelatinase-associated lipocalin (NGAL) | before surgery and at 2, 6, 12 h after declaming of renal artery | No |
Secondary | Hemodynamic parameters | arterial blood pressure, heart rate, central venous pressure, pulse oximetry | before surgery and at 2, 6, 12, 24, 48, 72 h after declaming of renal artery | Yes |
Secondary | outcome of kidney transplantation | number of acute rejection or number of delayed graft function | at 72 h after declaming of renal artery | No |
Secondary | postoperative hospital stay | length of postoperative hospital stay (days) | at postoperative day 60 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 |